(Q35047223)

6 August 2017

title

Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer (English)

1 reference

6 August 2017

1 reference

1 reference

1

Denise A Yardley

1 reference

6 August 2017

Lowell Hart

2

1 reference

6 August 2017

David Waterhouse

3

1 reference

6 August 2017

Robert Whorf

4

1 reference

6 August 2017

D Randolph Drosick

5

1 reference

6 August 2017

Patrick Murphy

6

1 reference

6 August 2017

Suprith Badarinath

7

1 reference

6 August 2017

Brooke R Daniel

8

1 reference

6 August 2017

Barrett H Childs

9

1 reference

6 August 2017

Howard Burris

10

1 reference

6 August 2017

language of work or name

English

0 references

publication date

21 November 2013

1 reference

Breast Cancer Research and Treatment

6 August 2017

published in

1 reference

6 August 2017

volume

142

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

655-665

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-013-2764-y

6 August 2017

exact match

0 references

cites work

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2764-Y

10.1007/S10549-013-2764-Y

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hgdbuic7d5gnfbljoder25oenu

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_hgdbuic7d5gnfbljoder25oenu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hgdbuic7d5gnfbljoder25oenu

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/hgdbuic7d5gnfbljoder25oenu

1 reference